nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2016-3-4-36-47nodgo-261Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ/ОБЗОРЫ ЛИТЕРАТУРЫORIGINAL INVESTIGATIONS/LITERATURE REVIEWSИндивидуализированная терапия нейробластомыIndividualized therapy in neuroblastomaСимонТ.SimonT.

Кельн, Германия

Cologne, Germany

thorsten.simon@uk-koeln.deФишерМ.FischerM.

Кельн, Германия

Cologne, Germany

ХероБ.HeroB.

Кельн, Германия

Cologne, Germany

Отделение детской онкологии и гематологии, Детская больница, Кельнский университетГерманияDepartment for Pediatric Oncology and Hematology, Children’s Hospital, University of CologneGermanyОтделение экспериментальной детской онкологии, Кельнский университетГерманияDepartment for Experimental Pediatric Oncology, Children’s Hospital, University of CologneGermany201617012017343647Copyright © Симон Т., Фишер М., Херо Б., 20172017Симон Т., Фишер М., Херо Б.Simon T., Fischer M., Hero B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/261

Нейробластома (НБ) – злокачественная эмбриональная опухоль детского возраста, характеризующаяся возможностью развития спонтанной регрессии у пациентов группы низкого риска или регрессии опухоли после проведения низкодозовой полихимиотерапии. В отличие от больных указанной группы большинство пациентов группы высокого риска имеют крайне неблагоприятный прогноз, несмотря на проведение интенсивной мультимодальной терапии. Поэтому НБ является идеальной моделью для внедрения индивидуализированных терапевтических подходов. В течение многих лет пациентам с НБ проводилось риск-адаптированное лечение в соответствии с клиническими характеристиками заболевания и молекулярными особенностями опухоли на момент постановки диагноза.В последнее время все большее значение приобретает внедрение подходов терапии, основанных на модификации лечения при проведении оценки ответа на проводимую терапию, а также использование таргетной молекулярной терапии, направленной против определенных молекулярно-генетических аномалий. Однако каждый терапевтический подход должен основываться на проспективных клинических исследованиях.

Neuroblastoma, a malignant embryonal tumor of early childhood, has the unique feature of regression after mild or even no chemotherapy in low risk patients. In contrast, most high-risk patients die of disease despite intensive multimodality treatments. It is, therefore, an ideal model tumor for establishing individualized therapies. For many years, neuroblastoma patients have undergone risk adapted treatment according to clinical and molecular characteristics of the patient and the tumor, respectively, at the time of diagnosis. Recently, other approaches such as treatment modifications based on response to treatment as well as targeted molecular therapies directed against distinct abnormal pathways are becoming increasingly important. Every approach must rely on prospectively evaluated treatment strategies.

детионкологиянейробластомаиндивидуализация леченияchildrenneuroblastomatreatment individualizationReferencesCohn, S.L., A.D. Pearson, W.B. London, et al., The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol, 2009. 27(2): p. 289-97.Cohn, S.L., A.D. Pearson, W.B. London, et al., The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol, 2009. 27(2): p. 289-97.London, W.B., L. Boni, T. Simon, et al., The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Lett, 2005. 228(1-2): p. 257-66.London, W.B., L. Boni, T. Simon, et al., The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Lett, 2005. 228(1-2): p. 257-66.Maris, J.M., M.J. Weiss, C. Guo, et al., Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol, 2000. 18(9): p. 1888-99.Maris, J.M., M.J. Weiss, C. Guo, et al., Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol, 2000. 18(9): p. 1888-99.Simon, T., R. Spitz, A. Faldum, et al., New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol, 2004. 26(12): p. 791-6.Simon, T., R. Spitz, A. Faldum, et al., New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol, 2004. 26(12): p. 791-6.Caron, H., P. van Sluis, J. de Kraker, et al., Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med, 1996. 334(4): p. 225-30.Caron, H., P. van Sluis, J. de Kraker, et al., Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med, 1996. 334(4): p. 225-30.Shimada, H., I.M. Ambros, L.P. Dehner, et al., Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer, 1999. 86(2): p. 349-63.Shimada, H., I.M. Ambros, L.P. Dehner, et al., Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer, 1999. 86(2): p. 349-63.Shimada, H., J. Chatten, W.A. Newton, Jr., et al., Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst, 1984. 73(2): p. 405-16.Shimada, H., J. Chatten, W.A. Newton, Jr., et al., Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst, 1984. 73(2): p. 405-16.George, R.E., S. Li, C. MedeirosNancarrow, et al., High-risk neuroblastoma treated with tandem autologous peripheralblood stem cell-supported transplantation: long-term survival update. J Clin Oncol, 2006. 24(18): p. 2891-6.George, R.E., S. Li, C. MedeirosNancarrow, et al., High-risk neuroblastoma treated with tandem autologous peripheralblood stem cell-supported transplantation: long-term survival update. J Clin Oncol, 2006. 24(18): p. 2891-6.Matthay, K.K., C.P. Reynolds, R.C. Seeger, et al., Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cisretinoic acid: a children's oncology group study. J Clin Oncol, 2009. 27(7): p. 1007-13.Matthay, K.K., C.P. Reynolds, R.C. Seeger, et al., Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cisretinoic acid: a children's oncology group study. J Clin Oncol, 2009. 27(7): p. 1007-13.Spitz, R., B. Hero, T. Simon, et al., Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res, 2006. 12(11 Pt 1): p. 3368-73.Spitz, R., B. Hero, T. Simon, et al., Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res, 2006. 12(11 Pt 1): p. 3368-73.Attiyeh, E.F., W.B. London, Y.P. Mosse, et al., Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med, 2005. 353(21): p. 2243-53.Attiyeh, E.F., W.B. London, Y.P. Mosse, et al., Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med, 2005. 353(21): p. 2243-53.Bown, N., S. Cotterill, M. Lastowska, et al., Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med, 1999. 340(25): p. 1954-61.Bown, N., S. Cotterill, M. Lastowska, et al., Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med, 1999. 340(25): p. 1954-61.Lastowska, M., S. Cotterill, N. Bown, et al., Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes Cancer, 2002. 34(4): p. 428-36.Lastowska, M., S. Cotterill, N. Bown, et al., Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes Cancer, 2002. 34(4): p. 428-36.Brodeur, G.M., J.E. Minturn, R. Ho, et al., Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res, 2009. 15(10): p. 3244-50.Brodeur, G.M., J.E. Minturn, R. Ho, et al., Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res, 2009. 15(10): p. 3244-50.Nakagawara, A., M. ArimaNakagawara, N.J. Scavarda, et al., Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med, 1993. 328(12): p. 847-54.Nakagawara, A., M. ArimaNakagawara, N.J. Scavarda, et al., Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med, 1993. 328(12): p. 847-54.Brodeur, G.M., TRK-a expression in neuroblastomas: a new prognostic marker with biological and clinical significance. J Natl Cancer Inst, 1993. 85(5): p. 344-5.Brodeur, G.M., TRK-a expression in neuroblastomas: a new prognostic marker with biological and clinical significance. J Natl Cancer Inst, 1993. 85(5): p. 344-5.Opel, D., C. Poremba, T. Simon, et al., Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res, 2007. 67(2): p. 735-45.Opel, D., C. Poremba, T. Simon, et al., Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res, 2007. 67(2): p. 735-45.Oberthuer, A., B. Hero, F. Berthold, et al., Prognostic impact of gene expressionbased classification for neuroblastoma. J Clin Oncol, 2010. 28(21): p. 3506-15.Oberthuer, A., B. Hero, F. Berthold, et al., Prognostic impact of gene expressionbased classification for neuroblastoma. J Clin Oncol, 2010. 28(21): p. 3506-15.Asgharzadeh, S., R. Pique-Regi, R. Sposto, et al., Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst, 2006. 98(17): p. 1193-203.Asgharzadeh, S., R. Pique-Regi, R. Sposto, et al., Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst, 2006. 98(17): p. 1193-203.Ohira, M., S. Oba, Y. Nakamura, et al., Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell, 2005. 7(4): p. 337-50.Ohira, M., S. Oba, Y. Nakamura, et al., Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell, 2005. 7(4): p. 337-50.Oberthuer, A., F. Berthold, P. Warnat, et al., Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol, 2006. 24(31): p. 5070-8.Oberthuer, A., F. Berthold, P. Warnat, et al., Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol, 2006. 24(31): p. 5070-8.Janoueix-Lerosey, I., G. Schleiermacher, E. Michels, et al., Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol, 2009. 27(7): p. 1026-33.Janoueix-Lerosey, I., G. Schleiermacher, E. Michels, et al., Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol, 2009. 27(7): p. 1026-33.Spitz, R., A. Oberthuer, M. Zapatka, et al., Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer, 2006. 45(12): p. 1130-42.Spitz, R., A. Oberthuer, M. Zapatka, et al., Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer, 2006. 45(12): p. 1130-42.Brodeur, G.M., J. Pritchard, F. Berthold, et al., Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol, 1993. 11(8): p. 1466-77.Brodeur, G.M., J. Pritchard, F. Berthold, et al., Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol, 1993. 11(8): p. 1466-77.Monclair, T., G.M. Brodeur, P.F. Ambros, et al., The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol, 2009. 27(2): p. 298-303.Monclair, T., G.M. Brodeur, P.F. Ambros, et al., The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol, 2009. 27(2): p. 298-303.De Bernardi, B., M. Gerrard, L. Boni, et al., Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol, 2009. 27(7): p. 1034-40.De Bernardi, B., M. Gerrard, L. Boni, et al., Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol, 2009. 27(7): p. 1034-40.Hero, B., T. Simon, R. Spitz, et al., Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol, 2008. 26(9): p. 1504-10.Hero, B., T. Simon, R. Spitz, et al., Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol, 2008. 26(9): p. 1504-10.Rubie, H., B. De Bernardi, M. Gerrard, et al., Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol, 2011. 29(4): p. 449-55.Rubie, H., B. De Bernardi, M. Gerrard, et al., Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol, 2011. 29(4): p. 449-55.Schleiermacher, G., V. Mosseri, W.B. London, et al., Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer, 2012. 107(8): p. 1418-22.Schleiermacher, G., V. Mosseri, W.B. London, et al., Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer, 2012. 107(8): p. 1418-22.Oberthuer, A., D. Juraeva, B. Hero, et al., Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers. Clin Cancer Res, 2015. 21(8): p. 1904-15.Oberthuer, A., D. Juraeva, B. Hero, et al., Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers. Clin Cancer Res, 2015. 21(8): p. 1904-15.Carlsen, N.L., Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening. Am J Pediatr Hematol Oncol, 1992. 14(2): p. 103-10.Carlsen, N.L., Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening. Am J Pediatr Hematol Oncol, 1992. 14(2): p. 103-10.Cheung, N.K., B.H. Kushner, M.P. LaQuaglia, et al., Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers. Eur J Cancer, 1997. 33(12): p. 2117-20.Cheung, N.K., B.H. Kushner, M.P. LaQuaglia, et al., Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers. Eur J Cancer, 1997. 33(12): p. 2117-20.Kushner, B.H., N.K. Cheung, M.P. LaQuaglia, et al., Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol, 1996. 14(2): p. 373-81.Kushner, B.H., N.K. Cheung, M.P. LaQuaglia, et al., Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol, 1996. 14(2): p. 373-81.Evans, A.E., J. Gerson, and L. Schnaufer, Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr, 1976. 44: p. 49-54.Evans, A.E., J. Gerson, and L. Schnaufer, Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr, 1976. 44: p. 49-54.Schilling, F.H., C. Spix, F. Berthold, et al., Neuroblastoma screening at one year of age. N Engl J Med, 2002. 346(14): p. 1047-53.Schilling, F.H., C. Spix, F. Berthold, et al., Neuroblastoma screening at one year of age. N Engl J Med, 2002. 346(14): p. 1047-53.Pinto, N.R., M.A. Applebaum, S.L. Volchenboum, et al., Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol, 2015. 33(27): p. 3008-17.Pinto, N.R., M.A. Applebaum, S.L. Volchenboum, et al., Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol, 2015. 33(27): p. 3008-17.Bertolini, P., M. Lassalle, G. Mercier, et al., Platinum compound-related ototoxicity in children: long-term followup reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol, 2004. 26(10): p. 649-55.Bertolini, P., M. Lassalle, G. Mercier, et al., Platinum compound-related ototoxicity in children: long-term followup reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol, 2004. 26(10): p. 649-55.Simon, T., B. Hero, W. Dupuis, et al., The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr, 2002. 214(4): p. 149-52.Simon, T., B. Hero, W. Dupuis, et al., The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr, 2002. 214(4): p. 149-52.Grewal, S., T. Merchant, R. Reymond, et al., Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics, 2010. 125(4): p. e938-50.Grewal, S., T. Merchant, R. Reymond, et al., Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics, 2010. 125(4): p. e938-50.Laverdiere, C., N.K. Cheung, B.H. Kushner, et al., Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer, 2005. 45(3): p. 324-32.Laverdiere, C., N.K. Cheung, B.H. Kushner, et al., Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer, 2005. 45(3): p. 324-32.Bhandari, S., N.K. Cheung, B.H. Kushner, et al., Hypothyroidism after 131Imonoclonal antibody treatment of neuroblastoma. Pediatr Blood Cancer, 2010. 55(1): p. 76-80.Bhandari, S., N.K. Cheung, B.H. Kushner, et al., Hypothyroidism after 131Imonoclonal antibody treatment of neuroblastoma. Pediatr Blood Cancer, 2010. 55(1): p. 76-80.Benz-Bohm, G., B. Hero, A. Gossmann, et al., Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma: how much diagnostic imaging is necessary? Eur J Radiol, 2010. 74(3): p. e1-5.Benz-Bohm, G., B. Hero, A. Gossmann, et al., Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma: how much diagnostic imaging is necessary? Eur J Radiol, 2010. 74(3): p. e1-5.Laverdiere, C., Q. Liu, Y. Yasui, et al., Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst, 2009. 101(16): p. 1131-40.Laverdiere, C., Q. Liu, Y. Yasui, et al., Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst, 2009. 101(16): p. 1131-40.Rubino, C., E. Adjadj, S. Guerin, et al., Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer, 2003. 107(5): p. 791-6.Rubino, C., E. Adjadj, S. Guerin, et al., Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer, 2003. 107(5): p. 791-6.Bhatti, P., L.H. Veiga, C.M. Ronckers, et al., Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res, 2010. 174(6): p. 741-52.Bhatti, P., L.H. Veiga, C.M. Ronckers, et al., Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res, 2010. 174(6): p. 741-52.Danner-Koptik, K.E., N.S. Majhail, R. Brazauskas, et al., Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant, 2013. 48(3): p. 363-8.Danner-Koptik, K.E., N.S. Majhail, R. Brazauskas, et al., Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant, 2013. 48(3): p. 363-8.Stutterheim, J., L. ZappeijKannegieter, R. Versteeg, et al., The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer, 2011. 47(8): p. 1193-202.Stutterheim, J., L. ZappeijKannegieter, R. Versteeg, et al., The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer, 2011. 47(8): p. 1193-202.Cheung, I.Y., Y. Feng, and N.K. Cheung, Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma. Pediatr Blood Cancer, 2013. 60(7): p. E32-4.Cheung, I.Y., Y. Feng, and N.K. Cheung, Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma. Pediatr Blood Cancer, 2013. 60(7): p. E32-4.Cai, J.Y., Y.J. Tang, L.M. Jiang, et al., Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma. Pediatr Blood Cancer, 2007. 49(7): p. 952-7.Cai, J.Y., Y.J. Tang, L.M. Jiang, et al., Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma. Pediatr Blood Cancer, 2007. 49(7): p. 952-7.Schmidt, M., T. Simon, B. Hero, et al., The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer, 2008. 44(11): p. 1552-8.Schmidt, M., T. Simon, B. Hero, et al., The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer, 2008. 44(11): p. 1552-8.Decarolis, B., C. Schneider, B. Hero, et al., Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol, 2013. 31(7): p. 944-51.Decarolis, B., C. Schneider, B. Hero, et al., Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol, 2013. 31(7): p. 944-51.Matthay, K.K., V. Edeline, J. Lumbroso, et al., Correlation of early metastatic response by 123Imetaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol, 2003. 21(13): p. 2486-91.Matthay, K.K., V. Edeline, J. Lumbroso, et al., Correlation of early metastatic response by 123Imetaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol, 2003. 21(13): p. 2486-91.Matthay, K.K., B. Shulkin, R. Ladenstein, et al., Criteria for evaluation of disease extent by (123)Imetaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer, 2010. 102(9): p. 1319-26.Matthay, K.K., B. Shulkin, R. Ladenstein, et al., Criteria for evaluation of disease extent by (123)Imetaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer, 2010. 102(9): p. 1319-26.Bagatell, R., K. McHugh, A. Naranjo, et al., Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. J Clin Oncol, 2016. 34(7): p. 740-6.Bagatell, R., K. McHugh, A. Naranjo, et al., Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. J Clin Oncol, 2016. 34(7): p. 740-6.Yu, A.L., A.L. Gilman, M.F. Ozkaynak, et al., Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med, 2010. 363(14): p. 1324-34.Yu, A.L., A.L. Gilman, M.F. Ozkaynak, et al., Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med, 2010. 363(14): p. 1324-34.Simon, T., B. Hero, A. Faldum, et al., Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer, 2011. 11: p. 21.Simon, T., B. Hero, A. Faldum, et al., Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer, 2011. 11: p. 21.Cheung, N.K., I.Y. Cheung, B.H. Kushner, et al., Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colonystimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol, 2012. 30(26): p. 3264-70.Cheung, N.K., I.Y. Cheung, B.H. Kushner, et al., Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colonystimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol, 2012. 30(26): p. 3264-70.Siebert, N., C. Eger, D. Seidel, et al., Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs, 2016: p. 1-13.Siebert, N., C. Eger, D. Seidel, et al., Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs, 2016: p. 1-13.Dickson, P.V., J.B. Hamner, T.L. Sims, et al., Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res, 2007. 13(13): p. 3942-50.Dickson, P.V., J.B. Hamner, T.L. Sims, et al., Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res, 2007. 13(13): p. 3942-50.Segerstrom, L., D. Fuchs, U. Backman, et al., The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res, 2006. 60(5): p. 576-81.Segerstrom, L., D. Fuchs, U. Backman, et al., The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res, 2006. 60(5): p. 576-81.Glade Bender, J.L., P.C. Adamson, J.M. Reid, et al., Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol, 2008. 26(3): p. 399-405.Glade Bender, J.L., P.C. Adamson, J.M. Reid, et al., Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol, 2008. 26(3): p. 399-405.Glade Bender, J.L., A. Lee, J.M. Reid, et al., Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol, 2013. 31(24): p. 3034-43.Glade Bender, J.L., A. Lee, J.M. Reid, et al., Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol, 2013. 31(24): p. 3034-43.Streby, K.A., N. Shah, M.A. Ranalli, et al., Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy. Pediatr Blood Cancer, 2015. 62(1): p. 5-11.Streby, K.A., N. Shah, M.A. Ranalli, et al., Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy. Pediatr Blood Cancer, 2015. 62(1): p. 5-11.George, S.L., N. Falzone, S. Chittenden, et al., Individualized 131ImIBG therapy in the management of refractory and relapsed neuroblastoma. Nucl Med Commun, 2016.George, S.L., N. Falzone, S. Chittenden, et al., Individualized 131ImIBG therapy in the management of refractory and relapsed neuroblastoma. Nucl Med Commun, 2016.Schmidt, M., T. Simon, B. Hero, et al., Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin, 2006. 45(4): p. 145-51; quiz N39-40.Schmidt, M., T. Simon, B. Hero, et al., Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin, 2006. 45(4): p. 145-51; quiz N39-40.Kraal, K.C., G.A. Tytgat, B.L. van EckSmit, et al., Upfront treatment of high-risk neuroblastoma with a combination of 131IMIBG and topotecan. Pediatr Blood Cancer, 2015. 62(11): p. 1886-91.Kraal, K.C., G.A. Tytgat, B.L. van EckSmit, et al., Upfront treatment of high-risk neuroblastoma with a combination of 131IMIBG and topotecan. Pediatr Blood Cancer, 2015. 62(11): p. 1886-91.de Kraker, J., K.A. Hoefnagel, A.C. Verschuur, et al., Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer, 2008. 44(4): p. 551-6.de Kraker, J., K.A. Hoefnagel, A.C. Verschuur, et al., Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer, 2008. 44(4): p. 551-6.Matthay, K.K., K. DeSantes, B. Hasegawa, et al., Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol, 1998. 16(1): p. 229-36.Matthay, K.K., K. DeSantes, B. Hasegawa, et al., Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol, 1998. 16(1): p. 229-36.Matthay, K.K., J.P. Huberty, R.S. Hattner, et al., Efficacy and safety of [131I] metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med, 1991. 35(4): p. 244-7.Matthay, K.K., J.P. Huberty, R.S. Hattner, et al., Efficacy and safety of [131I] metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med, 1991. 35(4): p. 244-7.Eleveld, T.F., D.A. Oldridge, V. Bernard, et al., Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet, 2015. 47(8): p. 864-71.Eleveld, T.F., D.A. Oldridge, V. Bernard, et al., Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet, 2015. 47(8): p. 864-71.Schramm, A., J. Koster, Y. Assenov, et al., Mutational dynamics between primary and relapse neuroblastomas. Nat Genet, 2015. 47(8): p. 872-7.Schramm, A., J. Koster, Y. Assenov, et al., Mutational dynamics between primary and relapse neuroblastomas. Nat Genet, 2015. 47(8): p. 872-7.Woodfield, S.E., L. Zhang, K.A. Scorsone, et al., Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer, 2016. 16: p. 172.Woodfield, S.E., L. Zhang, K.A. Scorsone, et al., Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer, 2016. 16: p. 172.Johnsen, J.I., L. Segerstrom, A. Orrego, et al., Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene, 2008. 27(20): p. 2910-22.Johnsen, J.I., L. Segerstrom, A. Orrego, et al., Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene, 2008. 27(20): p. 2910-22.Kiessling, M.K., A. CurioniFontecedro, P. Samaras, et al., Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS One, 2016. 11(1): p. e0147682.Kiessling, M.K., A. CurioniFontecedro, P. Samaras, et al., Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS One, 2016. 11(1): p. e0147682.Peirce, S.K., H.W. Findley, C. Prince, et al., The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol, 2011. 68(2): p. 325-35.Peirce, S.K., H.W. Findley, C. Prince, et al., The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol, 2011. 68(2): p. 325-35.Boller, D., A. Schramm, K.T. Doepfner, et al., Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res, 2008. 14(4): p. 1172-81.Boller, D., A. Schramm, K.T. Doepfner, et al., Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res, 2008. 14(4): p. 1172-81.Westhoff, M.A., G. Karpel-Massler, O. Bruhl, et al., A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. Mol Cell Ther, 2014. 2: p. 32.Westhoff, M.A., G. Karpel-Massler, O. Bruhl, et al., A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. Mol Cell Ther, 2014. 2: p. 32.Spunt, S.L., S.A. Grupp, T.A. Vik, et al., Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol, 2011. 29(21): p. 2933-40.Spunt, S.L., S.A. Grupp, T.A. Vik, et al., Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol, 2011. 29(21): p. 2933-40.Bagatell, R., R. Norris, A.M. Ingle, et al., Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatr Blood Cancer, 2014. 61(5): p. 833-9.Bagatell, R., R. Norris, A.M. Ingle, et al., Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatr Blood Cancer, 2014. 61(5): p. 833-9.Pugh, T.J., O. Morozova, E.F. Attiyeh, et al., The genetic landscape of high-risk neuroblastoma. Nat Genet, 2013. 45(3): p. 279-84.Pugh, T.J., O. Morozova, E.F. Attiyeh, et al., The genetic landscape of high-risk neuroblastoma. Nat Genet, 2013. 45(3): p. 279-84.Peifer, M., F. Hertwig, F. Roels, et al., Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature, 2015. 526(7575): p. 700-4.Peifer, M., F. Hertwig, F. Roels, et al., Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature, 2015. 526(7575): p. 700-4.Mosse, Y.P., Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies. Clin Cancer Res, 2016 . 22(3): p. 546-52.Mosse, Y.P., Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies. Clin Cancer Res, 2016 . 22(3): p. 546-52.Mosse, Y.P., M. Laudenslager, L. Longo, et al., Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 2008. 455(7215): p. 930-5.Mosse, Y.P., M. Laudenslager, L. Longo, et al., Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 2008. 455(7215): p. 930-5.Mosse, Y.P., M.S. Lim, S.D. Voss, et al., Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol, 2013. 14(6): p. 472-80.Mosse, Y.P., M.S. Lim, S.D. Voss, et al., Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol, 2013. 14(6): p. 472-80.Schulte, J.H., S. Schulte, L.C. Heukamp, et al., Targeted Therapy for Neuroblastoma: ALK Inhibitors. Klin Padiatr, 2013. 225(6): p. 303-8.Schulte, J.H., S. Schulte, L.C. Heukamp, et al., Targeted Therapy for Neuroblastoma: ALK Inhibitors. Klin Padiatr, 2013. 225(6): p. 303-8.Amin, A.D., L. Li, S.S. Rajan, et al., TKI sensitivity patterns of novel kinasedomain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. Oncotarget, 2016.Amin, A.D., L. Li, S.S. Rajan, et al., TKI sensitivity patterns of novel kinasedomain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. Oncotarget, 2016.Wang, Y., L. Wang, S. Guan, et al., Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Sci Rep, 2016. 6: p. 19423.Wang, Y., L. Wang, S. Guan, et al., Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Sci Rep, 2016. 6: p. 19423.Puissant, A., S.M. Frumm, G. Alexe, et al., Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov, 2013. 3(3): p. 308-23.Puissant, A., S.M. Frumm, G. Alexe, et al., Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov, 2013. 3(3): p. 308-23.Maris, J.M., Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma. Cancer Cell, 2009. 15(1): p. 5-6.Maris, J.M., Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma. Cancer Cell, 2009. 15(1): p. 5-6.Otto, T., S. Horn, M. Brockmann, et al., Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell, 2009. 15(1): p. 67-78.Otto, T., S. Horn, M. Brockmann, et al., Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell, 2009. 15(1): p. 67-78.Mosse, Y.P., E. Lipsitz, E. Fox, et al., Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective smallmolecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin Cancer Res, 2012. 18(21): p. 6058-64.Mosse, Y.P., E. Lipsitz, E. Fox, et al., Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective smallmolecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin Cancer Res, 2012. 18(21): p. 6058-64.DuBois, S.G., A. Marachelian, E. Fox, et al., Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol, 2016. 34(12): p. 1368-75.DuBois, S.G., A. Marachelian, E. Fox, et al., Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol, 2016. 34(12): p. 1368-75.Mujoo, K., D.A. Cheresh, H.M. Yang, et al., Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res, 1987. 47(4): p. 1098-104.Mujoo, K., D.A. Cheresh, H.M. Yang, et al., Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res, 1987. 47(4): p. 1098-104.Fakhari, M., D. Pullirsch, K. Paya, et al., Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J Pediatr Surg, 2002. 37(4): p. 582-7.Fakhari, M., D. Pullirsch, K. Paya, et al., Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J Pediatr Surg, 2002. 37(4): p. 582-7.Eggert, A., N. Ikegaki, J. Kwiatkowski, et al., High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res, 2000. 6(5): p. 1900-8.Eggert, A., N. Ikegaki, J. Kwiatkowski, et al., High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res, 2000. 6(5): p. 1900-8.

The authors declare that there are no conflicts of interest present.